Remus Pharma.
: REMUS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Remus Pharma.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Remus Pharma Ltd is engaged in the trading and export of Active Pharmaceutical Ingredients (API) and finished formulations, alongside providing technical consultancy services. The company specialises in therapeutic categories including Critical Care, Neurology, Cardiology, and Diabetes.
Business Model
The company operates an asset-light model, leveraging loan licences and contract manufacturing arrangements to produce its pharmaceutical formulations. It generates revenue through the marketing and export of these products and the provision of specialised technical consultancy.
Growth Outlook
The company is focusing on expanding its portfolio by incorporating off-patent molecules and complex generics to capture market share in its core therapeutic segments.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards in both domestic and international markets.
- Manufacturing Dependency. Reliance on third-party contract manufacturers and loan licence arrangements exposes the company to potential supply chain disruptions and quality control issues.
- Market Competition. The pharmaceutical trading and export sector is highly competitive, which may exert pressure on profit margins.
- Currency Fluctuation. As an exporter, the company is exposed to foreign exchange risks that could impact its financial performance.
Start your research today
Unlock AI insights, financials, peers and live data on Remus Pharma. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Remus Pharma.REMUS | ₹1,090 Cr | — | — | — | 32.0% | — | — | +3.7% |
Lincoln Pharmaceuticals LimitedLINCOLN | ₹1,232 Cr | 12.77 | 8.45 | 10.2% | 20.7% | 13.5% | 17.5% | +14.2% |
Themis MedicareTHEMISMED | ₹1,156 Cr | 28.91 | -38.17 | -12.8% | -9.9% | 10.0% | 11.3% | +26.6% |
Bajaj HealthcareBAJAJHCARE | ₹1,084 Cr | 59.63 | 11.02 | 12.3% | 18.5% | 3.5% | 9.3% | -23.7% |
Bharat Parenterals LimitedBPLPHARMA | ₹1,053 Cr | 37.14 | 16.34 | 9.4% | 21.2% | 8.3% | 9.0% | +12.3% |
KopranKOPRAN | ₹974 Cr | 39.03 | 17.75 | 12.0% | 9.1% | 4.8% | 7.7% | +30.3% |
As of Mar 2026
Financials
Remus Pharma.
: REMUS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Remus Pharma.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Remus Pharma Ltd is engaged in the trading and export of Active Pharmaceutical Ingredients (API) and finished formulations, alongside providing technical consultancy services. The company specialises in therapeutic categories including Critical Care, Neurology, Cardiology, and Diabetes.
Business Model
The company operates an asset-light model, leveraging loan licences and contract manufacturing arrangements to produce its pharmaceutical formulations. It generates revenue through the marketing and export of these products and the provision of specialised technical consultancy.
Growth Outlook
The company is focusing on expanding its portfolio by incorporating off-patent molecules and complex generics to capture market share in its core therapeutic segments.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards in both domestic and international markets.
- Manufacturing Dependency. Reliance on third-party contract manufacturers and loan licence arrangements exposes the company to potential supply chain disruptions and quality control issues.
- Market Competition. The pharmaceutical trading and export sector is highly competitive, which may exert pressure on profit margins.
- Currency Fluctuation. As an exporter, the company is exposed to foreign exchange risks that could impact its financial performance.
Start your research today
Unlock AI insights, financials, peers and live data on Remus Pharma. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026